You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Future developments in the medical treatment of abnormal uterine bleeding: what can we expect?

Simon, James A. MD, CCD, NCMP, FACOG

doi: 10.1097/gme.0b013e3182127b53
Special Section: Causality, Diagnosis & Management of Abnormal Uterine Bleeding

New therapies for abnormal uterine bleeding have been slow to reach the marketplace for a variety of reasons. These reasons include the availability of cost-effective therapies already available and the extraordinarily difficult and expensive regulatory barriers emphasizing long-term safety. Common comorbidities like bleeding diatheses, adenomyosis, and leiomyomata further complicate clinical development, necessitating large study samples and making it more expensive. Even the accurate measurement of menstrual blood loss adds an additional hindrance to novel drug development. These obstacles and the currently available therapies will be reviewed in the context of developing new methods for approaching this complicated and prevalent clinical problem.

Author Information

From the George Washington University School of Medicine and Women's Health and Research Consultants, Washington, DC.

Received November 16, 2010; revised and accepted January 26, 2011.

Funding/support: None reported.

Financial disclosure/conflicts of interest: Dr. James A. Simon has served asa consultant or on the advisory boards of Abbott Laboratories (Abbott Park,IL), Amgen Inc. (Thousand Oaks, CA), Ascend Therapeutics (Herndon, VA), Azur Pharma, Inc. (Fitzwilliam Square, Dublin, Ireland), BioSante (Lincolnshire, IL), Boehringer Ingelheim (Ingelheim, Germany), Depomed, Inc. (Menlo Park, CA), Fabre-Kramer (Houston, TX), Laboratoire HRA Pharma (Paris, France), Meditrina Pharmaceuticals (Ann Arbor, MI), Merck (Whitehouse Station, NJ), Merrion Pharmaceuticals (Wilmington, NC), NDA Partners LLC (Lakewood Ranch, FL), Novo Nordisk (Bagsværd, Denmark), Novogyne (East Hanover, NJ), Pfizer Inc. (New York, NY), Shionogi Inc. (Florham Park, NJ), Slate PharmaceuticalsInc. (Durham, NC), Teva Pharmaceutical Industries Ltd. (Jerusalem, Israel), Warner Chilcott (Rockaway, NJ), and Watson Pharmaceutical Inc. (Corona, CA). He has received grant/research support from BioSante (Lincolnshire, IL), Boehringer Ingelheim (Ingelheim, Germany), EndoCeutics Inc. (Quebec, Quebec), Novo Nordisk (Bagsværd, Denmark), Novogyne (East Hanover, NJ), and Teva Pharmaceutical Industries Ltd. (Jerusalem, Israel). He has also served on the speaker's bureaus of Amgen Inc. (Thousand Oaks, CA), Ascend Therapeutics (Herndon, VA), Bayer (Leverkusen, Germany), Boehringer Ingelheim (Ingelheim, Germany), Merck (Whitehouse Station, NJ), Novo Nordisk (Bagsværd, Denmark), Novartis (Basel, Switzerland), Novogyne (East Hanover, NJ), Teva PharmaceuticalIndustries Ltd. (Jerusalem, Israel), and Warner Chilcott (Rockaway,NJ).

Presented at the Premeeting Symposium: "Abnormal Uterine Bleeding: Causality, Diagnosis & Management"; October 6, 2010.

Address Please provide complete correspondence address.correspondence to: James A. Simon, MD, CCD, NCMP, FACOG, George Washington University School of Medicine, Women's Health and Research Consultants, 1850 M Street, NW, Suite 450 Washington, DC 20036.

©2011The North American Menopause Society